Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Illumina, Inc.

NASDAQ: ILMN · Industrial Applications and Services · 6 alerts · CIK 1110803

Share price
$198.00Close, Nov 16
Market cap
$29.9B
Shares outstanding
151.2MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Illumina, Inc. filings on SEC EDGAR ↗

5:19 PM ET Form 4
Insider Selling

Illumina Director Keith A. Meister Sells $61.1M of Stock

Keith A. Meister, Director, sold 280,091 shares of Illumina, Inc. at $212.97 to $222.44 a share (average $218.12) in 21 transactions, worth $61.1M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 208,826 (-0.9%).

Value
$61.1M
Shares
280,091
Average price
$218.12
Role
Director
Holding change
-0.9%
Trade date
Nov 9, 2026 to Nov 11, 2026
4:32 PM ET Form 4
Insider Selling

Illumina VP, CAO Scott D. Ericksen Sells $58.1K of Stock

Scott D. Ericksen, VP, CAO, sold 267 shares of Illumina, Inc. at $217.76 a share, worth $58.1K in total on Nov 10, 2026. Shares held after the trade: 14,029 (-1.9%).

Value
$58.1K
Shares
267
Price
$217.76
Role
VP, CAO
Holding change
-1.9%
Trade date
Nov 10, 2026
5:16 PM ET Form 4
Insider Selling

Illumina Director Keith A. Meister Sells $66.6M of Stock

Keith A. Meister, Director, sold 281,433 shares of Illumina, Inc. at $225.12 to $241.42 a share (average $236.50) in 13 transactions, worth $66.6M in total between Nov 3, 2026 and Nov 4, 2026. Shares held after the trade: 488,917 (-0.1%).

Value
$66.6M
Shares
281,433
Average price
$236.50
Role
Director
Holding change
-0.1%
Trade date
Nov 3, 2026 to Nov 4, 2026
4:15 PM ET 10-Q
Financial Results

Illumina Q3 2026 Results: Net Income $220M, Up 46.7% YoY

Illumina, Inc. reported total assets of $6.81 billion as of September 27, 2026, with a notable increase in goodwill and intangible assets following the acquisition of SomaLogic. The company reduced its current liabilities by paying down $499 million in term debt, while maintaining a cash position of $1.29 billion.

Key figure
Net income $220M · +46.7% YoY
4:08 PM ET 8-K
Financial Results

Illumina Financial Results

Illumina reported Q3 2026 revenue of $1.13 billion, up 4.2% year-over-year, driven by healthy clinical demand and robust NovaSeq X placements. Based on this momentum, the company raised its full-year 2026 revenue guidance to $4.64-$4.66 billion and non-GAAP EPS guidance to $5.40-$5.45.

“In the third quarter, healthy clinical demand and robust NovaSeq X placements drove results above our guidance. Based on continued momentum, we are raising our full year revenue and earnings guidance.”

Jacob Thaysen, Chief Executive Officer of Illumina

“As we continue to execute our strategy, our innovation is broadening the value of the Illumina ecosystem. Together with our customers, we are laying the foundation for AI to transform our understanding of human biology and improve patient outcomes.”

Jacob Thaysen, Chief Executive Officer of Illumina
4:49 PM ET 8-K
Loan & Debt

Illumina $1B Debt Financing

Illumina, Inc. established a new $1.0 billion unsecured commercial paper program to issue short-term notes for general corporate purposes. The notes will have maturities of up to 397 days and will be issued through three commercial paper dealers. As of the filing date, no notes were outstanding under the program.

Value
$1B
Term
up to 397 days

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.